RT Book, Section A1 Greene, Elisa M. A1 Hagemann, Tracy M. A2 DiPiro, Joseph T. A2 Yee, Gary C. A2 Posey, L. Michael A2 Haines, Stuart T. A2 Nolin, Thomas D. A2 Ellingrod, Vicki SR Print(0) ID 1182464083 T1 Drug-Induced Hematologic Disorders T2 Pharmacotherapy: A Pathophysiologic Approach, 11e YR 2020 FD 2020 PB McGraw-Hill Education PP New York, NY SN 9781260116816 LK accesspharmacy.mhmedical.com/content.aspx?aid=1182464083 RD 2024/03/28 AB KEY CONCEPTSThe most common drug-induced hematologic disorders are aplastic anemia, agranulocytosis, megaloblastic anemia, hemolytic anemia, and thrombocytopenia.Drug-induced hematologic disorders are rare adverse effects associated with drug therapy.The incidence of rare adverse drug reactions (ADRs) is usually established by postmarketing surveillance and reporting.Re-challenging a patient with an agent suspected of inducing a blood disorder is not generally recommended.Drug-induced hematologic disorders can occur by two mechanisms: direct drug or metabolite toxicity or an immune reaction.The primary treatment of drug-induced hematologic disorders is the removal of the drug in question and symptomatic support of the patient.